Previous 10 | Next 10 |
2024-06-22 12:45:00 ET With the 2024 U.S. presidential elections heating up next week in the form of the first debate, Goldman Sachs' portfolio strategy research team took a look at American companies which have the biggest exposure to domestic and international sales.... Read the ful...
2024-06-19 19:47:42 ET Summary Coatue Management's 13F portfolio value increased from $23.84B to $25.50B this quarter, with around 75 individual stock positions. New stakes include Qualcomm, Broadcom, Dell Technologies, and Constellation Energy, while stakes in Apple, Walt Disney,...
2024-06-18 15:03:18 ET More on GeoVax GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on GeoVax Historical earnings data for GeoVax Financial information for GeoVax Read the full article on Seeking Alpha...
2024-06-18 03:42:39 ET Summary Moderna's RSV vaccine has been approved by the FDA, but it faces competition from GSK and PFE's offerings. A June 26 meeting of the Advisory Committee on Immunization Practices is a near-term catalyst. MRNA is hoping for parity with GSK/PFE when it c...
2024-06-16 09:45:00 ET Moderna (NASDAQ: MRNA) is best known for its work in the coronavirus vaccine market. That's why the company's stock skyrocketed in the earlier days of the pandemic. It's also why its shares have lagged over the past three years -- its COVID-19 vaccine sales dr...
2024-06-14 15:21:25 ET Moderna ( MRNA ) shares traded in the red on Friday, making it the seventh straight day of losses. The stock is down 4.03% at $139.38.... Read the full article on Seeking Alpha For further details see: Moderna stock traded in the red for seven stra...
2024-06-13 18:34:04 ET More on BioNTech, Moderna, etc. BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcar...
2024-06-13 07:26:13 ET More on Moderna Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Moderna, Inc. (MRNA) Jefferies 2024 Global Healthcare Conference (Transcript) Moderna, Inc. (MRNA) Moderna Oncology Investor Event (Transcr...
mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age a...
2024-06-12 09:00:09 ET Hartaj Singh from Oppenheimer issued a price target of $179.00 for MRNA on 2024-06-12 07:41:00. The adjusted price target was set to $179.00. At the time of the announcement, MRNA was trading at $148.39. The overall price target consensus is at $16...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...